Preeclampsia | Crude incidence (%) 95Â % CI | Odds ratio (95Â % CI) | PAR (%) 95Â % CI | PAF (95Â % CI) |
---|---|---|---|---|
Controls/overall incidence* (n = 594) | 3.2 (1.9–5) | Reference | 6.5 (5.1–8.1)* |  |
Major rheumatic diseases (n = 67) | 26.9 (16.8–39.1) | 9.2 (4.3–19.5) | 1.4 (0.6–2.1) | 0.22 (0.09–0.33) |
UCTD (n = 131) | 13.7 (8.4–20.8) | 4.6 (2.3–9.2) | 1.4 (0.6–2.1) | 0.21 (0.1–0.31) |
Overall rheumatic diseases (n = 198) | 16.7 (11.8–22.6) | 6 (3.3–10.9) | 2.8 (1.7–3.9) | 0.43 (0.26–0.56) |
No criteria for diagnosis (n = 150) | 6 (2.8–11.1) | 2 (0.9–4.6) | 0.05 (−0.01–1.1) | 0.07 (−0.03–0.17) |
Fetal growth restriction (FGR) | ||||
 Controls/overall incidence* | 4.2 (2.8–6.1) | Reference | 8.8 (7.2–10.8)* |  |
 Major rheumatic diseases | 26.9 (16.8–39.1) | 8.8 (4.4–17.3) | 1.6 (0.9–2.4) | 0.18 (0.1–0.26) |
 UCTD | 16 (10.2–23.5) | 4.1 (2.2–7.8) | 1.5 (0.06–2.4) | 0.17 (0.07–0.26) |
 Overall rheumatic diseases | 19.7 (14.4–25.9) | 5.5 (3.2–9.5) | 3.1 (1.9–4.3) | 0.36 (0.22–0.47) |
 No criteria for diagnosis | 13.4 (8.4–20) | 3.6 (1.9–6.7) | 1.4 (0.05–2.3) | 0.16 (0.06–0.26) |
Preeclampsia or FGR | ||||
 Controls/overall incidence* | 6.1 (4.3–8.3) | Reference | 11.5 (9.6–13.5)* |  |
 Major rheumatic diseases | 29.9 (19.3–42.3) | 6.8 (3.6–12.9) | 1.7 (0.09–2.5) | 0.15 (0.08–0.21) |
 UCTD | 22.9 (16–31.1) | 4.4 (2.5–7.5) | 2.2 (1.1–3.2) | 0.19 (0.1–0.27) |
 Overall rheumatic diseases | 25.3 (19.4–31.9) | 5.1 (3.2–8.3) | 3.9 (2.6–9.6) | 0.34 (0.22–0.44) |
 No criteria for diagnosis | 14.8 (9.5–21.5) | 2.7 (1.5–4.8) | 1.4 (0.4–2.3) | 0.1 (0.04–0.2) |